Trade Galapagos NV - GLPG CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.25 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.022099% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.000123% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | Netherlands | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Galapagos NV ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 27.25 |
| Open* | 27.2 |
| 1-Year Change* | -20.93% |
| Day's Range* | 27 - 27.25 |
| 52 wk Range | 30.11-44.31 |
| Average Volume (10 days) | 89.86K |
| Average Volume (3 months) | 1.96M |
| Market Cap | 2.29B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 65.90M |
| Revenue | 601.43M |
| EPS | -2.60 |
| Dividend (Yield %) | N/A |
| Beta | 0.04 |
| Next Earnings Date | Feb 22, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 27.25 | 0.15 | 0.55% | 27.10 | 27.40 | 27.00 |
| Apr 19, 2024 | 27.15 | 0.35 | 1.31% | 26.80 | 27.15 | 26.75 |
| Apr 18, 2024 | 26.85 | -0.25 | -0.92% | 27.10 | 27.20 | 26.80 |
| Apr 17, 2024 | 27.30 | 0.20 | 0.74% | 27.10 | 27.55 | 26.75 |
| Apr 16, 2024 | 27.60 | -0.10 | -0.36% | 27.70 | 27.85 | 27.50 |
| Apr 15, 2024 | 28.00 | 0.10 | 0.36% | 27.90 | 28.50 | 27.90 |
| Apr 12, 2024 | 28.40 | -0.30 | -1.05% | 28.70 | 28.90 | 28.30 |
| Apr 11, 2024 | 28.80 | 0.10 | 0.35% | 28.70 | 29.00 | 28.50 |
| Apr 10, 2024 | 28.85 | -0.15 | -0.52% | 29.00 | 29.10 | 28.80 |
| Apr 9, 2024 | 29.05 | 0.10 | 0.35% | 28.95 | 29.20 | 28.75 |
| Apr 8, 2024 | 29.25 | 0.15 | 0.52% | 29.10 | 29.30 | 28.75 |
| Apr 5, 2024 | 29.10 | -0.15 | -0.51% | 29.25 | 29.40 | 28.90 |
| Apr 4, 2024 | 29.30 | 0.10 | 0.34% | 29.20 | 29.50 | 29.00 |
| Apr 3, 2024 | 29.25 | -0.15 | -0.51% | 29.40 | 29.45 | 29.05 |
| Apr 2, 2024 | 29.55 | 0.15 | 0.51% | 29.40 | 29.95 | 29.30 |
| Mar 28, 2024 | 29.45 | -0.80 | -2.64% | 30.25 | 30.30 | 28.95 |
| Mar 27, 2024 | 30.00 | -0.10 | -0.33% | 30.10 | 30.20 | 29.80 |
| Mar 26, 2024 | 30.00 | 0.15 | 0.50% | 29.85 | 30.30 | 29.80 |
| Mar 25, 2024 | 29.95 | -0.25 | -0.83% | 30.20 | 30.20 | 29.90 |
| Mar 22, 2024 | 30.35 | -0.10 | -0.33% | 30.45 | 30.55 | 30.10 |
Galapagos NV Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, April 24, 2024 | ||
| Time (UTC) 12:00 | Country BE
| Event Galapagos NV Annual Shareholders Meeting Galapagos NV Annual Shareholders MeetingForecast -Previous - |
| Tuesday, April 30, 2024 | ||
| Time (UTC) 12:00 | Country BE
| Event Galapagos NV Annual Shareholders Meeting Galapagos NV Annual Shareholders MeetingForecast -Previous - |
| Time (UTC) 13:00 | Country BE
| Event Galapagos NV Extraordinary Shareholders Meeting Galapagos NV Extraordinary Shareholders MeetingForecast -Previous - |
| Thursday, May 2, 2024 | ||
| Time (UTC) 10:59 | Country BE
| Event Q1 2024 Galapagos NV Earnings Release Q1 2024 Galapagos NV Earnings ReleaseForecast -Previous - |
| Friday, May 3, 2024 | ||
| Time (UTC) 10:59 | Country BE
| Event Q1 2024 Galapagos NV Earnings Call Q1 2024 Galapagos NV Earnings CallForecast -Previous - |
| Friday, August 2, 2024 | ||
| Time (UTC) 10:59 | Country BE
| Event Half Year 2024 Galapagos NV Earnings Call Half Year 2024 Galapagos NV Earnings CallForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 552.128 | 538.595 | 530.26 | 885.797 | 317.845 |
| Revenue | 552.128 | 538.595 | 530.26 | 885.797 | 317.845 |
| Total Operating Expense | 819.648 | 704.191 | 708.892 | 517.049 | 362.652 |
| Selling/General/Admin. Expenses, Total | 239.528 | 156.364 | 127.429 | 70.331 | 29.641 |
| Research & Development | 441.514 | 456.211 | 498.39 | 396.007 | 322.875 |
| Other Operating Expenses, Total | 60.961 | 55.344 | 66.079 | 39.899 | 10.136 |
| Operating Income | -267.52 | -165.596 | -178.632 | 368.748 | -44.807 |
| Interest Income (Expense), Net Non-Operating | 62.615 | 52.505 | -115.636 | -213.284 | 16.163 |
| Other, Net | -10.242 | -9.908 | -15.507 | -6.939 | -0.565 |
| Net Income Before Taxes | -215.147 | -122.999 | -309.775 | 148.525 | -29.209 |
| Net Income After Taxes | -217.991 | -125.422 | -311.001 | 148.69 | -29.259 |
| Net Income Before Extra. Items | -217.991 | -125.422 | -311.001 | 148.69 | -29.259 |
| Net Income | -217.991 | -103.231 | -305.436 | 149.846 | -29.259 |
| Total Adjustments to Net Income | -0.001 | ||||
| Income Available to Common Excl. Extra. Items | -217.991 | -125.422 | -311.001 | 148.689 | -29.259 |
| Income Available to Common Incl. Extra. Items | -217.991 | -103.231 | -305.436 | 149.845 | -29.259 |
| Dilution Adjustment | |||||
| Diluted Net Income | -217.991 | -103.231 | -305.436 | 149.845 | -29.259 |
| Diluted Weighted Average Shares | 65.699 | 65.5 | 65.075 | 60.1787 | 52.113 |
| Diluted EPS Excluding Extraordinary Items | -3.31803 | -1.91484 | -4.77912 | 2.47079 | -0.56145 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Diluted Normalized EPS | -2.701 | -1.78254 | -4.77912 | 2.47079 | -0.54794 |
| Depreciation / Amortization | 38.866 | 34.643 | 16.994 | 10.812 | |
| Total Extraordinary Items | 0 | 22.191 | 5.565 | 1.156 | |
| Cost of Revenue, Total | 12.079 | 1.629 | |||
| Gross Profit | 540.049 | 536.966 | |||
| Unusual Expense (Income) | 26.7 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 165.424 | 187.167 | 112.494 | 148.04 | 147.567 |
| Revenue | 165.424 | 187.167 | 112.494 | 148.04 | 147.567 |
| Total Operating Expense | 176.114 | 165.198 | 244.958 | 185.618 | 223.899 |
| Selling/General/Admin. Expenses, Total | 63.493 | 58.104 | 74.679 | 55.506 | 57.667 |
| Research & Development | 108.353 | 103.522 | 126.726 | 107.059 | 116.179 |
| Operating Income | -10.69 | 21.969 | -132.464 | -37.578 | -76.332 |
| Interest Income (Expense), Net Non-Operating | 29.148 | 1.491 | -71.598 | 62.871 | 59.672 |
| Net Income Before Taxes | 18.457 | 23.461 | -207.592 | 22.247 | -18.217 |
| Net Income After Taxes | 5.101 | 23.207 | -207.207 | 21.553 | -19.028 |
| Net Income Before Extra. Items | 5.101 | 23.207 | -207.207 | 21.553 | -19.028 |
| Total Extraordinary Items | 0 | 0 | 0 | ||
| Net Income | 5.101 | 23.207 | -207.207 | 21.553 | -19.028 |
| Income Available to Common Excl. Extra. Items | 5.101 | 23.207 | -207.207 | 21.554 | -19.028 |
| Income Available to Common Incl. Extra. Items | 5.101 | 23.207 | -207.207 | 21.554 | -19.028 |
| Diluted Net Income | 5.101 | 23.207 | -207.207 | 21.554 | -19.028 |
| Diluted Weighted Average Shares | 65.3594 | 66.3057 | 60.596 | 65.3151 | 65.7285 |
| Diluted EPS Excluding Extraordinary Items | 0.07805 | 0.35 | -3.41948 | 0.33 | -0.28949 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.07805 | 0.35 | -3.41948 | 0.33 | -0.02545 |
| Cost of Revenue, Total | 4.268 | 3.572 | 4.141 | 2.393 | 2.633 |
| Gross Profit | 161.156 | 183.595 | 108.353 | 145.647 | 144.934 |
| Other Operating Expenses, Total | 17.7 | 14.78 | 14.961 | ||
| Other, Net | -0.001 | 0.001 | -3.53 | -3.046 | -1.557 |
| Depreciation / Amortization | 21.712 | 5.88 | 5.759 | ||
| Unusual Expense (Income) | 0 | 0 | 26.7 | ||
| Total Adjustments to Net Income | 0.001 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 4236.85 | 4861.85 | 5369.35 | 5865.93 | 1328.85 |
| Cash and Short Term Investments | 4094.06 | 4703.18 | 5161.46 | 5780.83 | 1290.8 |
| Cash | 458.117 | 1225.86 | 1239.99 | 907.939 | 1091.55 |
| Cash & Equivalents | 0 | 199.243 | |||
| Short Term Investments | 3635.95 | 3477.32 | 3921.47 | 4872.89 | |
| Total Receivables, Net | 77.344 | 128.601 | 173.399 | 80.109 | 33.533 |
| Accounts Receivable - Trade, Net | 39.471 | 92.425 | 135.727 | 44.046 | 13.069 |
| Total Inventory | 52.925 | 20.569 | 0.355 | 0.255 | 0.276 |
| Prepaid Expenses | 0.488 | 0.202 | 0.219 | 0.292 | 0.142 |
| Other Current Assets, Total | 12.031 | 9.305 | 33.909 | 4.439 | 4.104 |
| Total Assets | 4734.35 | 5193.16 | 5717.73 | 6068.61 | 1439.5 |
| Property/Plant/Equipment, Total - Net | 154.252 | 137.512 | 103.378 | 66.052 | 23.137 |
| Property/Plant/Equipment, Total - Gross | 215.364 | 188.792 | 145.195 | 103.047 | 51.321 |
| Accumulated Depreciation, Total | -61.112 | -51.28 | -41.817 | -36.994 | -28.183 |
| Intangibles, Net | 146.354 | 60.103 | 67.565 | 24.927 | 3.632 |
| Note Receivable - Long Term | 119.941 | 127.186 | 161.624 | 93.407 | 73.443 |
| Other Long Term Assets, Total | 7.141 | 6.505 | 15.817 | 18.296 | 10.433 |
| Total Current Liabilities | 522.538 | 566.474 | 635.274 | 571.793 | 219.905 |
| Accounts Payable | 137.418 | 172.386 | 143.434 | 68.928 | |
| Accrued Expenses | 0.651 | ||||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 7.209 | 7.204 | 6.401 | 5.826 | 0 |
| Other Current Liabilities, Total | 366.673 | 421.852 | 456.487 | 422.533 | 150.977 |
| Total Liabilities | 2208.32 | 2549.8 | 3047.38 | 3192.95 | 225.247 |
| Total Long Term Debt | 14.692 | 19.655 | 23.035 | 19.558 | 0 |
| Capital Lease Obligations | 14.692 | 19.655 | 23.035 | 19.558 | |
| Other Liabilities, Total | 1650.95 | 1963.67 | 2389.07 | 2601.6 | 5.342 |
| Total Equity | 2526.03 | 2643.36 | 2670.35 | 2875.66 | 1214.25 |
| Common Stock | 293.604 | 292.075 | 291.312 | 287.282 | 236.54 |
| Additional Paid-In Capital | 2735.56 | 2730.39 | 2727.84 | 2703.58 | 1277.78 |
| Retained Earnings (Accumulated Deficit) | -501.542 | -377.382 | -345.608 | -114.065 | -298.514 |
| Other Equity, Total | -1.593 | -1.722 | -3.189 | -1.142 | -1.557 |
| Total Liabilities & Shareholders’ Equity | 4734.35 | 5193.16 | 5717.73 | 6068.61 | 1439.5 |
| Total Common Shares Outstanding | 65.8355 | 65.5527 | 65.4118 | 64.6668 | 54.4654 |
| Goodwill, Net | 69.813 | ||||
| Payable/Accrued | 148.005 | ||||
| Deferred Income Tax | 20.148 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 3956.09 | 4032.15 | 4155.29 | 4236.85 | 4462.4 |
| Cash and Short Term Investments | 3811.71 | 3874.94 | 3990.05 | 4094.06 | 4362.08 |
| Cash | 48.024 | 458.117 | 440.26 | ||
| Short Term Investments | 3652.33 | 3826.91 | 3865.92 | 3635.95 | 3921.82 |
| Total Receivables, Net | 73.044 | 67.576 | 67.569 | 66.555 | 54.374 |
| Accounts Receivable - Trade, Net | 46.918 | 41.45 | 41.443 | 40.429 | 34.783 |
| Other Current Assets, Total | 15.735 | 40.766 | 45.905 | 23.308 | 20.437 |
| Total Assets | 4451.34 | 4522.34 | 4632.17 | 4734.35 | 4972.07 |
| Property/Plant/Equipment, Total - Net | 136.803 | 134.728 | 134.888 | 154.252 | 150.394 |
| Intangibles, Net | 132.313 | 136.47 | 140.914 | 146.354 | 38.493 |
| Note Receivable - Long Term | 138.121 | 130.215 | 124.29 | 119.941 | 133.869 |
| Other Long Term Assets, Total | 18.144 | 19.102 | 7.114 | 7.141 | 11.923 |
| Total Current Liabilities | 444.036 | 475.073 | 522.904 | 522.538 | 532.207 |
| Accounts Payable | |||||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
| Current Port. of LT Debt/Capital Leases | 5.678 | 6.21 | 5.782 | 7.209 | 6.926 |
| Other Current Liabilities, Total | 317.229 | 337.789 | 361.173 | 366.654 | 370.536 |
| Total Liabilities | 1829.78 | 1938.39 | 2067.57 | 2208.32 | 2281.72 |
| Total Long Term Debt | 8.469 | 9.205 | 10.217 | 14.692 | 15.759 |
| Capital Lease Obligations | 8.469 | 9.205 | 10.217 | 14.692 | 15.759 |
| Other Liabilities, Total | 1351.95 | 1427.81 | 1514.82 | 1650.95 | 1733.75 |
| Total Equity | 2621.56 | 2583.95 | 2564.6 | 2526.03 | 2690.35 |
| Common Stock | 293.937 | 293.937 | 293.937 | 293.604 | 293.605 |
| Additional Paid-In Capital | 2736.99 | 2736.99 | 2736.99 | 2735.56 | 2735.56 |
| Retained Earnings (Accumulated Deficit) | -408.174 | -445.671 | -464.622 | -501.542 | -337.765 |
| Other Equity, Total | -1.196 | -1.311 | -1.704 | -1.593 | -1.046 |
| Total Liabilities & Shareholders’ Equity | 4451.34 | 4522.34 | 4632.17 | 4734.35 | 4972.07 |
| Total Common Shares Outstanding | 65.8971 | 65.8971 | 65.8971 | 65.8355 | 65.8355 |
| Total Inventory | 55.605 | 48.868 | 51.77 | 52.925 | 25.51 |
| Goodwill, Net | 69.863 | 69.678 | 69.672 | 69.813 | 174.994 |
| Payable/Accrued | 121.129 | 131.074 | 155.949 | 148.675 | 154.745 |
| Deferred Income Tax | 25.325 | 26.308 | 19.631 | 20.148 | |
| Cash & Equivalents | 159.375 | 124.135 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -217.991 | -103.231 | -305.436 | 149.845 | -29.259 |
| Cash From Operating Activities | -500.544 | -503.827 | -427.336 | 3009.7 | -142.466 |
| Cash From Operating Activities | 65.566 | 34.636 | 18.682 | 12.448 | 5.081 |
| Amortization | |||||
| Non-Cash Items | 43.407 | 5.461 | 213.636 | 222.788 | 11.615 |
| Cash Taxes Paid | 4.433 | 0.684 | 1.358 | 0.057 | 0.008 |
| Cash Interest Paid | 12.463 | 12.54 | 9.033 | 1.158 | 1.063 |
| Changes in Working Capital | -391.526 | -440.693 | -354.218 | 2624.61 | -129.903 |
| Cash From Investing Activities | -1245.51 | 541.238 | 757.288 | -3764.66 | -15.914 |
| Capital Expenditures | -36.947 | -57.879 | -91.315 | -45.685 | -13.717 |
| Other Investing Cash Flow Items, Total | -1208.57 | 599.117 | 848.603 | -3718.98 | -2.197 |
| Cash From Financing Activities | -1.487 | -3.876 | 22.04 | 1335.75 | 287.876 |
| Issuance (Retirement) of Stock, Net | 6.695 | 3.314 | 28.287 | 1345.29 | 303.845 |
| Issuance (Retirement) of Debt, Net | -8.182 | -7.19 | -6.247 | -5.091 | -0.005 |
| Foreign Exchange Effects | 22.293 | 56.763 | -70.539 | -9.966 | 10.089 |
| Net Change in Cash | -1725.25 | 90.298 | 281.453 | 570.82 | 139.585 |
| Financing Cash Flow Items | 0 | -4.447 | -15.964 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 23.207 | -217.991 | -10.784 | -32.338 | -13.31 |
| Cash From Operating Activities | -94.868 | -500.544 | -320.682 | -203.74 | -61.969 |
| Cash From Operating Activities | 65.566 | 43.854 | 37.974 | 5.516 | |
| Non-Cash Items | 21.942 | 43.407 | -69.661 | -28.294 | 7.261 |
| Cash Taxes Paid | 0.651 | 4.433 | 3.637 | 3.262 | 0.799 |
| Cash Interest Paid | 2.944 | 12.463 | 10.94 | 7.417 | 3.964 |
| Changes in Working Capital | -140.017 | -391.526 | -284.091 | -181.082 | -61.436 |
| Cash From Investing Activities | -288.669 | -1245.51 | -1263.62 | -1081.06 | -933.453 |
| Capital Expenditures | -4.284 | -36.947 | -29.116 | -17.357 | -9.665 |
| Other Investing Cash Flow Items, Total | -284.385 | -1208.57 | -1234.51 | -1063.7 | -923.788 |
| Cash From Financing Activities | -0.19 | -1.487 | 0.432 | -0.361 | -0.025 |
| Issuance (Retirement) of Stock, Net | 1.77 | 6.695 | 6.695 | 3.619 | 2.16 |
| Issuance (Retirement) of Debt, Net | -1.96 | -8.182 | -6.263 | -3.98 | -2.184 |
| Foreign Exchange Effects | -0.254 | 22.293 | 26.026 | 24.586 | 16.358 |
| Net Change in Cash | -383.981 | -1725.25 | -1557.85 | -1260.57 | -979.089 |
| Financing Cash Flow Items | -0.001 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Galapagos NV Company profile
About Galapagos NV
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Galapagos NV revenues increased 2% to EUR538.6M. Net loss before extraordinary items decreased 60% to EUR125.4M. Revenues reflect Total net revenues increase of 1% to EUR484.8M, Other operating income increase of 3% to EUR53.7M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR4.78 to -EUR1.92.
Equity composition
23754226 shares @12/31/04 1 for 4 split = shares 5938556 ipo may 2005 = shares 9170167 @ 06/30/05 H1 figures
| Industry: | Biotechnology & Medical Research (NEC) |
Generaal De Wittelaan L11 A3
MALINES (MECHELEN)
ANTWERPEN 2800
BE
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com